You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al

https://doi.org/10.1136/annrheumdis-2021-220764

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Gerd-Rüdiger R Burmester

    • Contributors MB and DA drafted this response.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles